Company Overview
- Website
- opsistx.com
- Employees
- 2
- Founded in
- 2016
- Industry
- BioTech/Drugs
- SIC Code
-
8731 - Commercial Physical and Biological Research
Financials & Stats
Revenue
$3B
Recent News & Media
The Pipeline for of iPSC-Derived Cell Therapeutics in 2025
- Jun 19, 2025
- bioinformant.com
BlueRock Receive FDA clearance of IND for Investigational iPSC-derived Cell Therapy OpCT-001
- Sep 9, 2024
- bioinformant.com
FDA grants IND clearance for BlueRock's primary photoreceptor disease cell therapy
- Sep 4, 2024
- glance.eyesoneyecare.com
BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases
- Sep 3, 2024
- bayer.com
BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics
- Jul 25, 2024
- bioinformant.com
Partnering News: Fujifilm Cellular Dynamics & GSK
- Jan 25, 2024
- dcatvci.org
Companies Similar to Opsis Therapeutics
Analyze industry trends and opportunities by examining competitors and companies comparable to Opsis Therapeutics, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 3M | 2 | Cambridge, MA | 2005 | |
| 3M | 7 | New York, NY | 2008 | |
| 3M | 3 | New York, NY | ||
| 3M | 2 | Knoxville, TN | 2004 | |
| 3M | 35 | Austin, TX |